Viridian Therapeutics Quarterly Cash Flow Statement
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viridian Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Viridian Therapeutics generated -$105.3 million of operating cash flow and spent $1.3 million on capital expenditures. That left free cash flow of -$106.6 million, a free-cash-flow margin of -37545.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Viridian Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -127.12M | -104.90M | -120.36M | -34.60M | -100.73M | -86.91M | -79.72M | -76.69M | -64.99M | -48.54M | -66.86M | -47.66M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 117.00K | 121.00K | 120.00K | 110.00K | 113.00K | 117.00K | 123.00K | 130.00K | 142.00K | 145.00K | 150.00K | 135.00K |
| Stock-Based Compensation | 16.98M | 13.39M | 11.99M | 11.25M | 10.84M | 10.22M | 8.97M | 8.72M | 11.77M | 12.69M | 26.05M | 13.61M |
| Change in Working Capital | -1.49M | -21.39M | 11.35M | 9.53M | 15.94M | -13.93M | 388.00K | 2.85M | 11.03M | -4.96M | 5.33M | -4.08M |
| Operating Cash Flow | -105.32M | -119.65M | -23.75M | -84.61M | -75.37M | -92.65M | -73.33M | -67.71M | -46.06M | -45.22M | -38.00M | -38.98M |
| Capital Expenditures | -1.31M | -23.00K | -240.00K | -127.00K | -42.00K | -86.00K | -114.00K | -293.00K | -104.00K | 0 | -48.00K | -404.00K |
| Investing Cash Flow | -231.16M | 77.26M | -339.42M | 126.08M | 75.72M | 100.06M | -62.91M | -84.67M | 61.98M | -143.04M | -169.71M | 48.04M |
| Debt Issued | — | — | — | — | — | — | 0 | — | — | — | 0 | 15.00M |
| Financing Cash Flow | 325.12M | 6.36M | 405.91M | 10.86M | 764.00K | 9.21M | 35.52M | 245.02M | 108.00K | 177.08M | 198.94M | 15.46M |
| Net Change in Cash | -11.36M | -36.04M | 42.73M | 52.32M | 1.11M | 16.62M | -100.72M | 92.65M | 16.03M | -11.19M | -8.77M | 24.52M |
| Free Cash Flow | -106.63M | -119.68M | -23.99M | -84.74M | -75.42M | -92.74M | -73.45M | -68.00M | -46.16M | -45.22M | -38.05M | -39.39M |
This table shows 12 quarterly periods of Viridian Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VRDN's reporting calendar. What is a cash flow statement?